|
|
Blood, 1 September 2008, Vol. 112, No. 5, pp. 1600-1609.
Prepublished online as a Blood First Edition Paper on June 20, 2008; DOI 10.1182/blood-2008-04-152850.
 Previous Article | Next Article 
Submitted April 18, 2008
Accepted June 9, 2008
European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas
Nancy J. Senff, Evert M. Noordijk, Youn H. Kim, Martine Bagot, Emilio Berti, Lorenzo Cerroni, Reinhard Dummer, Madeleine Duvic, Richard T. Hoppe, Nicola Pimpinelli, Steven T. Rosen, Maarten H. Vermeer, Sean Whittaker, and Rein Willemze*
Dept. of Dermatology, Leiden University Medical Center, Leiden, Netherlands
Dept. of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
Dept. of Dermatology, Stanford University School of Medicine, Stanford, CA, United States
Dept. of Dermatology, Hopital Henri Mondor, Creteil, France
Dept. of Dermatology, University of Milan-Biococca and Fondazione Ospedale Policlinico, Regina Elena and Mangiagalli, IRCC, Milan, Italy
Dept. of Dermatology, Medical University of Graz, Graz, Austria
Dept. of Dermatology, University Hospital of Zurich, Zurich, Switzerland
Dept. of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Dept. of Radiation Oncology, Stanford University Medical Center, Stanford, CA, United States
Dept. of Dermatology, University of Florence, Florence, Italy
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, United States
Skin Tumour Unit, St. John's Institute of Dermatology, St. Thomas' Hospital, London, United Kingdom
* Corresponding author; email: rein.willemze{at}planet.nl.
Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20-25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) consensus classification for cutaneous lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms was introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centres, which may be due to the fact that consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the three main groups of CBCL. Since no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state of the art management as currently practised in major cutaneous lymphoma centres. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. Hildenbrand, D.E. Craven, R. Jones, and P. Nemeskal
Lyme Neuroborreliosis: Manifestations of a Rapidly Emerging Zoonosis
AJNR Am. J. Neuroradiol.,
June 1, 2009;
30(6):
1079 - 1087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grange and F. Antonicelli
Cutaneous Lymphomas: What Can We Learn From Location?
Arch Dermatol,
June 1, 2009;
145(6):
710 - 712.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Willemze, M. Dreyling, and On behalf of the ESMO Guidelines Working Group
Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv115 - iv118.
[Full Text]
[PDF]
|
|
|
|
|
